Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 472 followers
Latest posts
Last updated 2 days ago
GSK on track to deliver 2024 outlooks with further good progress made in R&D
2 days ago
Q3 2024 performance highlights
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
3 days ago
Agreement reinforces GSK’s portfolio in the treatment of lupus and underlying drivers...
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
8 days ago
Single dose of vaccine elicited robust immune response with acceptable safety profile...
GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
11 days ago
GSK is investing more than £50 million in the CG-TIC to further...
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
16 days ago
Studies from OPERA and Trio cohorts provide further real-world evidence.
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
16 days ago
Gepotidacin could be the first in a new class of oral antibiotic...
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
18 days ago
Depemokimab is an ultra-long-acting biologic administered once every six months
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
22 days ago
60 abstracts to be presented across broad and growing portfolio of vaccines...
Statement: Zantac (ranitidine) litigation – settlement agreements reached
23 days ago
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac...
GSK presents positive data for Arexvy, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
24 days ago
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety...
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
25 days ago
At least two million doses of long-acting cabotegravir for PrEP to be...
GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion
about 1 month ago
Marketing authorisation in EU expected by November 2024.